Nalfurafine

Drug Profile

Nalfurafine

Alternative Names: AC-820; MT-9938; Nalfurafine hydrochloride; Nopicor; REMITCH; TRK-820; Winfuran

Latest Information Update: 27 Dec 2016

Price : $50

At a glance

  • Originator Toray
  • Developer Fresenius Medical Care; Japan Tobacco; Maruho; Mitsubishi Tanabe Pharma Corporation; SK Chemicals; Toray; Torii Pharmaceutical
  • Class Antipruritics; Morphinans; Opioid analgesics; Small molecules; Spiro compounds
  • Mechanism of Action Opioid kappa receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pruritus
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Pruritus
  • Discontinued Atopic dermatitis; Cancer pain; Neuropathic pain

Most Recent Events

  • 01 Nov 2016 Phase-I clinical trials in Pruritus in Bulgaria, Germany (PO) (NCT03002233)
  • 20 May 2015 Registered and launched for Pruritus (Treatment-experienced; In non-uraemic patients with chronic liver disease) in Japan (PO)
  • 05 Mar 2015 Torii and Sumitomo Dainippon Pharma sign a promotional agreement for nalfurafine
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top